I don’t know Ezra yet but since he’s taking the time to blog (which I hugesly respect) and share thoughts I thought I’d take him up on his challenge and also spill the beans on my secrets. On blogging I blog because I love it. My other secret on blogging? MORE

Cybersecurity company Proofpoint, which helped slow the sweeping global ransomware attack WannaCry after it emerged Friday, has now discovered a much more insidious, profitable, and potentially widespread cyberattack called Adylkuzz. Adylkuzz doesn’t demand, as WannaCry does, that victims pay a ransom to retrieve their data. Adylkuzz makes no announcement when it quietly invades target computers. MORE

Over the holiday I became aware of a new tech blog that aims to have deep insights into the next generation of technology, which they call The Hypernet. MORE

Uncertainty surrounding this year’s presidential election has kept U.S. IPO activity at a sluggish pace—so sluggish, in fact, that this year could end with the fewest IPOs and the lowest level of capital raised since 2009, according to PitchBook data for the first nine months of 2016. MORE

Folks had just clocked out last Friday when the Trump Administration announced a travel ban that threw airports around the country into chaos. That announcement set the tone for this week in life sciences. Many in biopharma blasted Trump’s order and tried to grapple with its implications. MORE

Thanks to remarkable results in a small group of patients, including former U.S. President Jimmy Carter , cancer immunotherapy has spurred talk of once impossible-to-imagine cures and has gained its share, perhaps more than its share, of hype. MORE

It’s a struggle that comic-book fans know well. Ordinary people, bestowed with super powers from a spider bite or gamma rays, struggle to harness their own abilities. T cells, key soldiers of the immune system, are wrestling with new-found super powers, too. MORE

’Tis the season for giving gifts. And increasingly, those shiny new toys and gadgets can be connected to the Internet—from TVs to watches, speakers to Barbie dolls. That Internet connection opens up a ton of possibilities for how we can use and enjoy our new devices. MORE

Boston blog main Boulder/Denver blog main Detroit blog main Indiana blog main National National blog main New York blog main Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Adynxx Allergan Amgen Anokion ARCH Venture Partners Ariad Pharmaceuticals Assembly Biosciences Biogen Biotech CureVac deals Donald Trump Ed Kaye Eteplirsen Exondys 51 FDA gender diversity George Scangos Hill-Rom Holdings J.P. MORE

A group of more than 100 prominent life sciences executives, investors, and business leaders have signed an open letter calling on the industry to step up efforts to increase gender diversity. The letter was published Wednesday , on the second to last day of the annual J.P. MORE

The American Association for Cancer Research held its annual meeting this week in Washington, DC, a convenient venue for former Vice President Joe Biden to deliver a broadside against the Trump administration’s proposed budget cuts in science funding. For Biden, it’s personal. MORE

Boston blog main Detroit blog main National blog main National top stories San Diego San Diego blog main San Diego top stories San Francisco blog main Texas blog main Aira Aira.io After beta testing technology that provides remote assistant services for the blind, San Diego-based Aira has raised $12 million in a Series B round that it says will enable the company to expand its service to thousands of visually impaired users this year. MORE

MORE

Two dramatic healthcare stories played out this week. First, to the jubilation of the nation’s science community, Congress proposed to boost National Institutes of Health funding, not slash it as the Trump administration had outlined. MORE

Prices for agricultural commodities such as corn, soy, and wheat are at their lowest levels in years, but investment in agricultural technology has never been better. MORE

It may have been a short holiday week, but there was plenty of news on the CRISPR front. In the ongoing battle for rights to the landmark gene editing technology, the faction led by the University of California appealed the U.S. decision in favor of the Broad Institute. Elsewhere, Bristol-Myers Squibb flipped assets, a top dealmaker made an unexpected tack into the perilous waters of Alzheimer’s drug development, and the SEC cracked down on stock pumping schemes. Let’s round it all up. MORE

Drivers have plenty of ways to communicate with their fellow drivers, beyond the basic turn signal. Some methods are nice, like a friendly wave to beckon a merging car into your lane. Others, not so much. We’ve all probably cursed or honked at another driver, or been given the finger. MORE

President Trump’s order to bar refugees and immigrants from seven Muslim-majority countries is on temporary hold, and a court hearing later today could eventually force a ruling by the U.S. Supreme Court. One of the latest biotech executives to speak out against the ban is in the backyard of Mitch McConnell (R-KY), the top Republican in the U.S. Senate. MORE

View the Slideshow It is a time of great transitions in the technology and business world. Key advances in areas like machine intelligence, agriculture, and healthcare seem poised to transform society—and everyday life. MORE

MORE

The blowback from U.S. business leaders to President Trump’s travel ban continues—today from a throng of biotech executives. This morning, 165 U.S. biotech leaders have signed a letter voicing “deep concern and opposition” to the order, which bars entry to the U.S. to refugees and immigrants from seven Muslim-majority countries. The Jan. 27 order placed a 90-day ban on immigrants from Iraq, Iran, Syria, Sudan, Somalia, Libya, and Yemen. MORE

We continue our look ahead to some of the clinical data due in 2017 that could shape healthcare practice and sway investor sentiment for years to come. Part one of our preview is here , with looks at key studies in lung cancer, Alzheimer’s disease, asthma, and more. In part two, we examine studies in leukemia, migraine, multiple sclerosis, Parkinson’s disease, postpartum depression, amyloidosis, and Zika virus vaccine. MORE

According to several news reports, the Trump administration will nominate Scott Gottlieb to be the new commissioner of the FDA, a selection that had the life sciences industry breathing a sigh of relief Friday afternoon. MORE

It’s 4.50am. Sunday morning. And I couldn’t sleep. I have much on my mind since I just returned from a week on the road. 5 days. 3 cities. Late night Mexican food. Beers. Airports. Delays. I left on a Sunday. I had to miss a full day with my family, camping in the mountains. MORE

I used to love blogging. Blogging proved to be a great way to hone my ideas, have public conversations with people and as it turns out – build meaningful relationships through public dialog that spilled over into the real world. Somewhere along the way blogging changed. Fred Wilson said as much in his blog post today, too. I guess it’s just a reality of blogging and I accept that. I like “single take” blogging. MORE

The company said the redesign came after finding that users were interested in using its tools to create blog-like travel and trip journals, rather than the original, animated slideshows the tool provided. networking social blogging travel iphone hipgeo MORE

If power in the business world is centered in the boardroom, women in biotech have a long way to go to get their fair share—and the venture community deserves much of the blame. MORE

As far as singular weeks go for biotech, this was a big one. Three highly anticipated drugs were approved. One is the first injectable medication for eczema. Another might help fend off the recurrence of ovarian cancer. And a third offers hope for people with severe forms of multiple sclerosis. Another drug, a new combination therapy for cystic fibrosis, could follow this year after succeeding in two large tests. Each drug might help change how these diseases will be treated for years to come. MORE

It’s been more than a year since an infamous party with hired models in cocktail dresses captured the biotech community’s attention at the 2016 J.P. Morgan conference. There has been plenty of talk since about closing biotech’s notable gender gap. At this year’s J.P MORE

Exhausted by the nonstop drama in Washington, DC? Immerse yourself instead in this week’s biotech headlines. Let’s start with a tribute to a life sciences icon, then we’ll head around the Xconomy network with early news from the nation’s big yearly cancer meeting. There was also momentum onthe IPO front and new gigs for high-profile folks (with just one stop on Capitol Hill along the way, we promise). Let’s get right to it. MORE

Blogs. By definition, you read blogs. People often ask me why I started blogging. I often get the question from people, “I’d like to blog, but I don’t really know what to talk about?&# My suggestion is to blog about your industry. You need a blog. MORE

“New York, New York, it’s a hell of a town. The Bronx is up, but we’re Brooklyn down.” ” For all you old-school Brooklyn swingers out there, we’ll take a short break from the madness in the nation’s capital and start our roundup in the greatest city in the world. You might disagree if you’ve got biotech dreams. MORE

Boston Boston blog main Boston top stories Boulder/Denver blog main Detroit blog main Indiana blog main National blog main National top stories New York blog main New York top stories Raleigh-Durham blog main San Diego blog main San Francisco blog main Seattle blog main Texas blog main Wisconsin blog main Cognitive Computing Conduent Cybersecurity Healthcare IT Healthtech IBM IBM Research Internet of Everything IoE IoT people R&D Sophie Vandebroek Xerox MORE

Fundraising is tough for startups but it’s particularly difficult in agriculture, a sector that has fewer firms focused on agtech investments. The dynamics are starting to change, though. MORE

6 or 7 years ago when TechCrunch was at its peak market share (they are still strong but many more tech blogs have also popped up) there was a term for getting covered there called “the TechCrunch bounce.” that they probably read the main tech blogs. MORE

Who knew healthcare could be so complicated ? This week, President Trump and the GOP saw first hand, as a feverish rally to get their healthcare bill through the House of Representatives on Thursday stalled before a vote. Elsewhere in Washington DC, drug pricing continued to be a political football. MORE